Welcoming ReSync Bio and Sphinx Bio: Building the future of AI in biotech

The future of biotech will be shaped by teams who know both science and software. Today, we’re welcoming two of the best: the ReSync Bio team, joining us now, and the Sphinx Bio team, who came aboard earlier this summer and are already making an impact.

AI is accelerating science, and Benchling is powering the shift

There’s no shortage of excitement about AI in science, and we share it. But the transformation hasn’t happened yet. Much of R&D remains manual, fragmented, and harder than it should be. 

At Benchling, we’re focused on making the promise of AI real. That means building tools that are designed for the lab, connected to real data, and trusted by scientists. It also means working with the people who’ve already started building that future.

Today, an entirely new generation of startups, like ReSync Bio and Sphinx Bio, are at the forefront of AI, biology, and software. 

What they build and why it matters

ReSync Bio was founded by Mihir Trivedi to help R&D teams move faster from idea to clinic. They built a platform that made it easier to manage compute and experimental workflows for complex drug discovery programs. ReSync’s marketplace of AI models for drug discovery made it simple to run the latest computational tools without needing to write code.

Sphinx Bio, founded by Nicholas Larus-Stone, developed an analysis platform that gives scientists direct access to their experimental data, without needing to wrangle across different data sources or tools. Their goal was simple but powerful: help scientists make better decisions, faster. 

We came away deeply impressed after spending time with Nicholas and Mihir. They represent the next generation of founders building tools for scientific progress, and have the rare ability to blend modern engineering, product thinking, and scientific reality. 

They are already making an impact at Benchling. Nicholas and the Sphinx team have been instrumental in advancing our AI roadmap. Their work is driving key initiatives like our Deep Research and Data Entry agents, and more. 

A growing ecosystem, a shared vision

When we started Benchling, there were very few software startups building for science. I’m inspired by how much that ecosystem has since flourished and the rare but growing group of people who can translate between the languages of science and software.

That’s the kind of talent Benchling was built around. For the right teams, Benchling can be a platform where their work scales to reach the entire industry fast, whether through partnership or by joining us directly. If you're working on something ambitious or thinking about what’s next, email me. The future of biotech is being built now. Come build it with us.